Merck & Co. Scores Breakthrough Win With mRNA Melanoma Therapy
On August 19, 2026, Merck & Co. and Moderna reported positive Phase 3 results for their mRNA-based neoantigen therapy intismeran in combination with Keytruda.
The treatment met primary and key secondary endpoints for recurrence-free and distant metastasis-free survival in patients with resected stage IIB, IV melanoma, without any new safety issues.
This breakthrough marks the first positive late-stage readout for both an individualized neoantigen therapy and an mRNA cancer treatment, showcasing a potential new approach to personalized immuno-oncology care using each patient's unique tumor fingerprint.
Merck's long-term investment narrative is likely to be reshaped by this success, as the company's broad late-stage pipeline aims to gradually rebalance its reliance on Keytruda while addressing pricing and policy pressures.